Cite
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
MLA
Amy S. Rosenberg, et al. “Cross-Reactive Immunologic Material Status Affects Treatment Outcomes in Pompe Disease Infants.” Molecular Genetics and Metabolism, vol. 99, Jan. 2010, pp. 26–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdfd705646917312bdc59de9df6e1b79&authtype=sso&custid=ns315887.
APA
Amy S. Rosenberg, Hanna Mandel, Paula Goldenberg, Stephanie L. Dearmey, Daniel K. Benjamin, Dwight D. Koeberl, Yuan-Tsong Chen, Deeksha Bali, Priya S. Kishnani, James H. Heller, Jennifer S. Li, Sue Ann Smith, & Sarah P. Young. (2010). Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Molecular Genetics and Metabolism, 99, 26–33.
Chicago
Amy S. Rosenberg, Hanna Mandel, Paula Goldenberg, Stephanie L. Dearmey, Daniel K. Benjamin, Dwight D. Koeberl, Yuan-Tsong Chen, et al. 2010. “Cross-Reactive Immunologic Material Status Affects Treatment Outcomes in Pompe Disease Infants.” Molecular Genetics and Metabolism 99 (January): 26–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdfd705646917312bdc59de9df6e1b79&authtype=sso&custid=ns315887.